DNAtrix Has Been Named as One of the “Top Advanced Therapies Projects to Watch” and Will Present at the Therapeutic Area Partnerships
Houston, TX – (BUSINESS WIRE – November 18, 2013) – DNAtrix Inc., a biotech company focusing on the development of oncolytic viruses for cancer, announced today that the lead clinical program from the company, DNX-2401, has been selected as one of the “Top Advanced Therapies Projects to Watch” by Elsevier. As the result of this recognition, Dr. Frank Tufaro, chief executive officer of DNAtrix, will be presenting at Elsevier Business Intelligence’s Therapeutic Area Partnerships Conference taking place in Boston on November 19, 2013 at 2:55 pm Eastern time.
According to David Cassak, Vice President, Content, Elsevier Business Intelligence, “Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees consider among the most attractive opportunities the industry has to offer. Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities, potential for new opportunities beyond initial indications and corporate stability.”
“We are honored to be chosen as one of the top 10 by Elsevier,” said Dr. Tufaro. “We believe DNX-2401 holds great promise for patients diagnosed with primary brain tumors. I look forward to sharing these exciting results along with our program and pipeline at the conference.”
DNX-2401 uses a genetically modified adenovirus that can only replicate and kill tumor cells. It is currently being developed for the treatment of several cancer indications including patients with recurrent glioblastoma. DNX-2401 is the most potent and effective oncolytic virus delivered to human brain tumors to date. In an earlier Phase I dose-escalating monotherapy study conducted with DNX-2401 in the US for patients with recurrent glioblastoma, efficacy results have been extremely promising with seven patients surviving longer than one year and to date, one patient surviving over three years. A phase Ib trial using the same virus in combination with temozolomide is currently being conducted in Spain for recurrent glioblastoma.
About DNAtrix, Inc.
DNAtrix is a privately held company developing modified viruses for treating cancer. The company has offices located in Houston, Texas and San Diego, California. For more information, please visit the company website at http://www.dnatrix.com.